Symbiotec Pharmalab Q2 FY27 Share Price & Earnings Call Analysis

₹1,642.40+6.75% today
Market cap
₹10,553 Cr
P/E
71.38
ROE
11.74%
PEG
1.01
Price to sales
12.14
Debt to equity
0.25
52W high / low
₹1,194 / ₹934
Sales growth (5Y)
6.55%
EBITDA margin
27.46%
Net profit margin
13.27%
Promoter holding
33.28%
Sales (last year)
₹869 Cr

Symbiotec is a research-driven, science- based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale Steroid manufacturer into a fully integrated global platform.[1]

Guidance scorecard · Q2 FY27 call

What Symbiotec Pharma's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#27of 87 in
Pharmaceuticals & Biotechnology

RevenueQ2 FY27 call

20–40%
  • API business is expected to grow at a high single-digit to low double-digit rate annually, driven primarily by volume growth and improved product and geography mix.
  • The steroid hormone segment remains a strong base, with continued potential expansion into new products and geographies, supporting consistent demand and pricing.
  • Complex injectable business anticipates recurring milestone revenues year-on-year, with sales and profit expected to kick in by the end of the next fiscal year.
  • Fermentation CDMO vertical has substantial growth headroom with existing 10-year take-or-pay contracts; Phase 1 expansion (~750 KL capacity) will scale revenues in FY28-'29 and beyond with multi-million liter capacities planned.

2 more points from Symbiotec Pharma's call on revenue

Create a free account to keep reading this call

Full Q2 FY27 analysis

MarginsQ2 FY27 call

Flat

See what Symbiotec Pharma said on margins — free account, 30 seconds.

Full Q2 FY27 analysis

CapexQ2 FY27 call

Planned
  • Capex investment for H1 FY27 stood at INR113 crores; net debt as of Sept 30 at INR314 crores.
  • Committed to corporate-level capex of INR200-300 crores annually, including biologics and biomanufacturing expansion.
  • Large capex for bio-CDMO business (increase from 600 KL to 750 KL capacity) backed by long-term take-or-pay customer agreements.
  • Significant capex for new biologics plant (~INR100 crores) focusing on insulin and analogs, with some delays due to regulatory updates.
  • Capex is partly shared with customers via strategic partnerships and milestone payments.
  • Future expansions planned at Ujjain fermentation CDMO site; acquired additional 40 acres to create a 70-72 acre mega facility.

2 more points from Symbiotec Pharma's call on capex

Create a free account to keep reading this call

Full Q2 FY27 analysis

FundraisingQ2 FY27 call

Planned

See what Symbiotec Pharma said on fundraising — free account, 30 seconds.

Full Q2 FY27 analysis

Order bookQ2 FY27 call

  • Symbiotec signed a legally binding 10-year take-or-pay agreement with a large European alternate protein customer for multi-million liter fermentation capacity, including Phase 0 (existing 100 KL capacity), Phase 1 (750 KL additional capacity), and…
  • Phase 0 production expected within the fiscal year; Phase 1 production to start next fiscal year.
  • The agreement is exclusive for the European customer covering global distribution, including US, Europe, and potentially Indian markets.
  • Multiple advanced discussions are ongoing with around 4 biomanufacturing customers for new CDMO opportunities.
  • The company has a multi-tens of millions USD milestone payment-based tie-up for injectable products focused on the US market, with discussions active for Europe and China.

2 more points from Symbiotec Pharma's call on the order book

Create a free account to keep reading this call

Full Q2 FY27 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. 1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,041 Cr33.1
240%+Up 2%+₹492 Cr19.6
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,347 Cr—
540%+Flat₹8,432 Cr32.4
640%+Flat₹4,295 Cr—

Financials of Symbiotec Pharma

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Symbiotec Pharma

Shareholding breakup across reporting periods.

Sep 2026
Promoters +33.28%
FIIs +3.79%
DIIs +33.17%
Public +29.77%
No. of Shareholders81,747

Financials of Symbiotec Pharma

Quarterly Results

Quarter-by-quarter operating performance

Jun 2025Sep 2025Mar 2026Jun 2026Sep 2026
Sales +203196245218280
YoY Sales growth+7%+43%
Expenses +145145183173188
Operating Profit5850624592
OPM %29%26%25%21%33%
Other Income +30000
Interest56766
Depreciation1111202222
Profit before tax4533351864
Tax %33%43%22%20%19%
Net Profit +3019281452
EPS in Rs46.9930.184.392.248.05

Financials of Symbiotec Pharma

Profit & Loss

Annual income statement trend

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +633682567716752869
Sales growth+8%-17%+26%+5%+16%
Expenses +438550497544549630
Operating Profit19513170172203239
OPM %31%19%12%24%27%27%
Other Income +73674-6
Interest73881726
Depreciation222629394353
Profit before tax17310539132147153
Tax %28%27%38%23%34%28%
Net Profit +123782310097110
EPS in Rs22.5414.174.2918.29151.9817.51
Dividend Payout %0%0%0%0%0%0%

Financials of Symbiotec Pharma

Balance Sheet

Capital structure and asset base

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital11111111111313
Reserves5105886117048041,1371,348
Borrowings +4765218247544391336
Other Liabilities +200152151326220240347
Total Liabilities7688159901,2891,5801,7812,044
Fixed Assets +2612802994484381,1201,091
CWIP284018220856864138
Investments5554144
Other Assets +474490504628572592811
Total Assets7688159901,2891,5801,7812,044

Financials of Symbiotec Pharma

Cash Flows

Operating, investing and financing cash movement

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +174186918847175
Cash from Investing Activity +-96-32-220-206-307-227
Cash from Financing Activity +-79151462227836
Net Cash Flow-11-5319-16
Free Cash Flow87-55-155-22-261-50
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit112%36%124%129%40%99%

Financials of Symbiotec Pharma

Ratios

Working capital efficiency and return ratios

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days687772648583
Inventory Days308252305382321274
Days Payable15591110259109160
Cash Conversion Cycle221238267187298197
Working Capital Days8612110776-3-22
ROCE %18%6%16%14%13%

Guidance history

How Symbiotec Pharma's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY27 call →20–40%FlatPlannedPlanned—
Q1 FY27 call →20–40%FlatPlannedPlannedRising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

What Symbiotec Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Vineet Laborator (Q2 FY27)

    Year-on-year change: Decrease of approximately INR 323.65 lakh or about 18.58% decline . Key results statement takeaways from Vineet Laboratories Ltd's Q2 FY27

  • Balaxi Pharma (Q2 FY27)

    34.1% increase (from Rs. Key results statement takeaways from Balaxi Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Alkem Lab (Q2 FY27)

    Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY. Key investor presentation takeaways from Alkem Laboratories Ltd's Q2 FY27 investor pres

  • Caplin Point Laboratories Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹629.84 crore, up 17.9% YoY (compared to ₹534.04 crore in Q2 FY26). Key investor presentation takeaways from Caplin Point Labor